Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3085)	9/25/2015 12:39:40 PM
From: scaram(o)uche	Respond to of 3202

AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-End - AbbVie to opt-out of collaboration with Galapagos on filgotinib NORTH CHICAGO, Ill., Sept. 25, 2015 /PRNewswire/ -- AbbVie (ABBV), a global biopharmaceutical company, today announced that it will advance ABT-494, its internally developed investigational selective JAK1 inhibitor, to Phase 3 studies in rheumatoid arthritis. Following a thorough review of available data, AbbVie will not exercise its right to in-license the Galapagos JAK1 inhibitor, filgotinib. "We believe ABT-494 has the potential to become a best-in-class therapy for patients," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "In our view, ABT-494 also offers a faster path to Phase 3 development with less uncertainty." Per the terms of the agreement with Galapagos, all rights to filgotinib will revert solely to Galapagos. (snip)

To: scaram(o)uche who wrote (3085)	9/25/2015 1:08:41 PM
From: scaram(o)uche	Respond to of 3202

>> we will advance ABT-494 to Phase 3 studies with a once-daily formulation.<< 6 mg twice daily looks very good. A daily dose of 12 mg looks every bit as good as 36. Going forward with 24 once daily seems like a tiny risk.... maybe 50 patients or so, each group, and it still looks like there may be some noise. (ACR70, 12 mg, Balance-II). Given this data, they certainly can't opt for 12 or 18 mg once daily?? From ct.gov, could only find evidence of one formulation having been tested. Guess they get warm and fuzzies from 24 mg ACR20 and trough levels of 494.